Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug ...

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...